Democrats Choosing Less Risky Path on Drug Prices
By BY MARGOT SANGER-KATZ
The Upshot
https://ift.tt/3keo3v1
Experts say recent compromises could create less harm in balancing innovation with profits.
New York Times
Drugs (Pharmaceuticals), Prices (Fares, Fees and Rates), Law and Legislation, Biotechnology and Bioengineering, Regulation and Deregulation of Industry
November 6, 2021 at 07:00AM